Cisplatin resistance is associated with reduced interferon-γ-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells

British Journal of Cancer

Volumn 76, Issue 10, 1997, Pages 1328-1332

  Marth, C ^a,b   Widschwendter, M ^a   Kaern J ^b   Jorgensen N P ^b   Windbichler, G ^a   Zeimet, A G ^a   Trope C ^b   Daxenbichler, G ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cisplatin resistance; Interferon; Oncogene HER 2; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; CISPLATIN; GAMMA INTERFERON; HLA DR ANTIGEN; MESSENGER RNA;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL;

EID: 0030657470     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.556     Document Type: Article

References (23)

1. Andrews PA and Howell SB (1990) Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2: 35-43
2. erbH 2 signaling enhances cisplatin-induced cytoxicity in human breast carcinoma cells: Association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 54: 3758-3765.
3. Benz CC, Scott GK, Sarup JC, Shepard HM and Osborne CK (1991) Tamoxifen resistance associated with p185HER-2 overexpression in human breast cancer cells transfected with HER-2/neu. proc Am Assoc Cancer Res 32: 1260
4. Chon SY, Hassanain HH and Gupta SL (1996) Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gamma-inducible expression of humun indoleamine 2,3-dioxygenase gene. J Biol Chem 271: 17247-17252
5. Guille: MJ, Laxton CD, Rutherford MN, Williams BR and Kerr IM (1994) Functional differences in the promoters of the interferon-inducible (2′-5′)A oligoadenylate synthetase and 6-16 genes in interferon-resistant Daudi cells. Eur J Biochem 219: 547-553
6. Hamaguchi K, Godwin AK, Yakushij M, O'Dwyer PJ, Ozols RF and Hamilton TC (1993) Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian carcinoma cell lines. Cancer Res 53: 5225-5232.
7. Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP and Shawver LK (1991) A monoclonal antibody against the c-erbB-2 protein enhances the cytoxicity of cis-diaminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51: 4575-4580
8. Hayes DF (1996) Should we treat HER, too? J Clin Onol 14: 697-699
9. Langton BC, Brink J, Xuan JA, Ciardello F and Salomon D (1993) Effects of oncogene expression on MHC class I expression and response to cisplatin in a mammary tumor cell line. Proc Am Assoc Cancer Res 34: 387
10. Langton-Webster BC, Xuan JA, Brink JR and Salomon DS (1994) Development of resistance to cisplatin is associated with decreased expression of the gp185c-erbB-2 protein and alterations in growth properties and responses to therapy in an ovarian tumor cell line. Cell Growth Different 5: 1367-1372
11. Marth C, Gastl G, Zech J, Zilla P, Mayer I, Fasol R, Huber C and Daxenbichler G (1987) Characterization of an interferon-resistant mutant of the human breast cancer cell line BT-20. J Interferon Res 7: 195-202
12. Marth C, Helmberg M, Mayer I, Fuith LC, Daxenbichler G and Dapunt O (1989a) Effects of biological response modifiers on ovarian carcinoma cell lines. Anticancer Res 9: 461-468
13. Marth C, Fuith LC, Böck G, Daxenbichler G and Dapunt O (1989b) Modulation of ovarian carcinoma tumor marker CA-125 by interferon-gumma Cancer Res 49: 6538-6542
14. Marth C, Müller-Holzner E, Greiter E, Cronauer MV, Zeimel AG, Doppler W, Eibl B, Hynes N and Daxenbichler G (1990) Interferon-γ reduces expression of the protooncogene cerbB-2 in human ovarian carcinoma cells. Cancer Res 50: 7037-7041
15. Nehmé A, Julia AM, Jozan S, Chevreau C, Bugat R and Canal P (1994) Modulation of cisplatin cytotoxicity by human recombinant interferon gamma in human ovarian-cancer cell lines. Eur J Cancer 30A: 520-525
16. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB and Slamon DJ (1994) Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9: 1829-1838
17. Pujade-Lauraine E, Guastalla JP, Colombo N, Devillier P, Francois E, Fumoleau P, Monnier A, Nooy M, Mignot L, Bugat R, Marques C, Mousseau M, Netter F, Larbaoui S and Brandely M (1996) Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 14: 343-350
18. Tsai CM, Levitzki A, Wu LH, Chang KT, Cheng CC, Gazit A and Perng RP (1996) Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells, Cancer Res 56: 1068-1074
19. Van der Zee AGJ, Hollema HH, De Bruijn HWA, Willemse PHB, Boonstra H, Mulder NH, Aalders JG and De Vries EGE (1995) Cell biological markers of drug resistance in ovarian carcinoma. Gynecol Oncol 58: 165-178
20. Walker TL, White JD, Esdale WJ, Burton MA and DeCruz EE (1996) Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression. Br J Cancer 73: 619-614
21. Widschwendter M, Daxenbichler G, Dapunt O and Marth C (1995) Effects of retinoic acid and γ-Interferon on expression of retinoic acid receptor and cellular retinoic acid-binding protein in breast cancer cells. Cancer Res 55: 2135-2139
22. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Sailo T and Toyoshima K (1986) Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nuture 319: 230-234
23. Zhang L and Hung MC (1996) Sensitization of HER-2/neu-overexpressjng non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene 12: 571-576